Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline. Sanofi’s participation, alongside other healthcare investors, will support the progression of Sensorion’s genetic medicine pipeline, particularly SENS-601 (GJB2-GT). SENS-601 is Sensorion’s second gene therapy candidate to progress towards clinical trials, following SENS-501, which entered clinical development in 2024. The company plans to use approximately €56m of net proceeds from the reserved offering primarily for research and development related to its gene therapy programmes SENS-501 and SENS-601, as well as for general research and development and corporate expenses. “With the additional capital, the company plans to intensify the ongoing efforts to progress the research and development of SENS-601, including the advancement of the programme into its clinical development, and to continue the clinical development of the SENS-501 programme.